Radionuclide therapy of adrenal tumors.
Adrenal tumors arising from chromaffin cells will often accumulate radiolabeled metaiodobenzylguanidine (MIBG) and thus are amenable to therapy with I-131 MIBG. More recently, therapy studies have targeted the somatostatin receptors using Lu-177 or Y-90 radiolabeled somatostatin analogs. Because pheochromocytoma (PHEO)/paraganglioma (PGL) and neuroblastoma (NB), which often arise from the adrenals, express these receptors, clinical trials have been performed with these reagents. We will review the experience using radionuclide therapy for targeting PHEO/PGL and NBs.
Molecular Imaging and Therapy Service, Radiology Department Memorial Sloan Kettering, USA. carrasj1@mskcc.org
Jorge A
JA
Carrasquillo
Neeta
N
Pandit-Taskar
Clara C
CC
Chen
D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D000818:Animals; D006801:Humans; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D019275:Radiopharmaceuticals